Paclitaxel enhancer compounds

Details Paclitaxel enhancer compounds Paclitaxel enhancer compounds

2008-03-18

2008-03-18

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S614000, C514S615000, C564S074000, C564S123000

Reexamination Certificate

active

07345094

ABSTRACT:
Disclosed is a compound represented by the Structural Formula (I):Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—.R1and R2are independently an aryl group or a substituted aryl group, R3and R4are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.R5-R6are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.R7and R8are each independently —H, an aliphatic or substituted aliphatic group, or R7is —H and R8is a substituted or unsubstituted aryl group, or, R7and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.Z is ═O or ═S.Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.

REFERENCES:
patent: 4012360 (1977-03-01), Schwarzenbach et al.
patent: 6013836 (2000-01-01), Hsu et al.
patent: 6172108 (2001-01-01), Vega et al.
patent: 6172188 (2001-01-01), Thastrup et al.
patent: 6235787 (2001-05-01), Broadhurst et al.
patent: 6365745 (2002-04-01), Matsui et al.
patent: 6399659 (2002-06-01), Usui et al.
patent: 6435787 (2002-08-01), John
patent: 6455515 (2002-09-01), Gypser et al.
patent: 6656971 (2003-12-01), Wu et al.
patent: 6703426 (2004-03-01), Miles et al.
patent: 6762204 (2004-07-01), Koya et al.
patent: 6800660 (2004-10-01), Koya et al.
patent: 6924312 (2005-08-01), Koya et al.
patent: 7001923 (2006-02-01), Koya et al.
patent: 7037940 (2006-05-01), Koya et al.
patent: 2005/0009920 (2005-01-01), Koya et al.
patent: 2037257 (1972-02-01), None
patent: 2097737 (1972-04-01), None
patent: 50-91056 (1975-07-01), None
patent: 50-91056 (1976-07-01), None
patent: WO 94/10995 (1994-05-01), None
patent: WO 99/34796 (1999-07-01), None
patent: WO 03/006428 (2003-01-01), None
patent: WO 03/006430 (2003-01-01), None
A. Oncology, vol. 13, pp. 1743-1748, 2002.
Cancer, vol. 106, No. 2, Jan. 15, 2006, pp. 375-382.
Chuyguk, V. A. and Nemazanyj A.G., “Mesoionic Methine Dyes from Biquaternary Salts of Dihetarylmethanes—1,3,4-Oxa(thia)diazoles and 1,2,4-Triazoles Derivatives,”Ukr. Khim. Zhurn.48:520 (1984).
“REMARKS” paper as submitted by applicant's attorney.
Stalteri, M.A., et al., “Site-specific conjugation and labelling of prostate antibody 7E11C5.3 (CYT-351) with technetium-99m,”European Journal of Nuclear Medicine24(6):651-654, (1997).
Twomey, D., “Anticancer Agents-IX. Derivatives of Pyridine, Pyridazine and Phthalazine,”Proceedings of the Royal Irish Academy, vol. 74, Sect. B:37-52,(1974).
Schwarz et al., CA77:48081, 1972.
Rupp, Walter, CA76:126992, 1972.
Barry, V. C. , et al., “Anticancer Agents-III. Synthesis and Anticancer Activity of Some Bis-Thiosemicarbazones and Thoiosemicarbazides,”Proc. R.I.A. 65:309-324 (1967).
O'Callaghan, C. N., “Anticancer Agents-X. Cyclisation of 1-Acyl-4-Alkylthiosemicarbazide Derivatives to 1,2,4-Triazoline-3-Thiones in the Presence of Hydrazine,”Proc. R.I.A. 74:455-461 (1974).
Molina, P., et al., XP-01118868 “Methyl 2-Methyldithiocarbazate in Heterocyclic Synthesis: Preparation of 2,5-Disubstituted 1,3,4-Thiadiazoles, Bis(1,3,4-Thiadiazolium) Salts and Macrocycles containing 1,3,4-Thiadiazole Subunits, X-Ray Crystal Structure of 2,2′-Bis[4,5-dihydro-5-(2-hydroxyethylimino)-4-methyl-1,3,4-thiadiazole],”J. Chem. Soc. Perkin Trans. 1 s5:1159-1166 (1991).
Molina, P., et al., XP-001118802 “Preparation of a Novel Type of Ligands Incorporating Two or Three 1,3,4-Thiadiazole Units,”Heterocycles36(6):1263-1278 (1993).
H. Bräuniger, “Hydrazide und Hydrazidderivate von Dicarbonsäuren,” Pharmaceutical-Chemical Institute of University of Rostock, Supplied by the “British Library” 25(5-6) 279-283 (1970).
Al-Talib, M. et al., “Diacyl Acid Dihydrazides,” Magnetic Resonance in Chemistry 28:1072-1078 (1990).
Chuiguk, V.A., and Nemazanyi, A.G., “Mesoionic Methine Dyes Of Biquaternary Salts Of Diheteroaryl Methanes—Derivatives Of 1, 3, 4—oxa (thia) Diazoles and 1, 2, 4—Triazoles,” Kiev. Gos. Univ., Kiev, USSR, Ukrainskii Khimicheskii Zhurnal, Russian Edition, 50(5):519-524 (1984). Abstract, Accession No. 1984:630420, HCAPLUS Database.
Barrett, William G. and McKay, Donald, “Decomposition and Cycloaddition Reactions of Some Bis(azodicarbonyl) Compounds,” Journal of Chem. Soc. (4):1046-1052 (1975).
Mitsui Toatsu Chem. Inc., Abstract of Japanese Patent No. 308024, published Dec. 25, 1986. from Derwent Publications Ltd.
Honshu Paper Mfg. Co. Ltd, Abstract of Japanese Patent No. 182050, published Feb. 13, 1996.
Asahi Chemical Ind. KK. Abstract of Japanese Patent No. 50-91056, Accession No. 47521Y/27 (1975).

Affiliated with

Also associated with

Rating

Paclitaxel enhancer compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Paclitaxel enhancer compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Paclitaxel enhancer compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2790794